Actualités Adial Pharmaceuticals Inc - ADIL | Actions NASDAQ

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Current Report Filing (8-k)

0001513525 false 0001513525 2023-03-06 2023-03-06 0001513525...

Adial Pharmaceuticals Provides Update on Regulatory Strategy for AD04 for Treatment of Alcohol Use Disorder

Company to pursue path toward U.S. and European approvals; Type C meeting with FDA confirmed for Q2 2023;...

Adial Pharmaceuticals Schedules Business Update Conference Call

CHARLOTTESVILLE, Va., March 02, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW...

Current Report Filing (8-k)

0001513525 false 0001513525 2023-02-28 2023-02-28 0001513525...

Adial Pharmaceuticals Announces Closing of $0.75 Million At-The-Market Registered Direct Offering

CHARLOTTESVILLE, Va., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW...

Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy...

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)

Filed Pursuant to Rule 424(b)(5) Registration No. 333-237793 PROSPECTUS SUPPLEMENT (To the Prospectus dated April 30...

Current Report Filing (8-k)

0001513525 false 0001513525 2023-02-23 2023-02-23 0001513525...

Adial Pharmaceuticals Announces Pricing of $0.75 Million At-The-Market Registered Direct Offering

CHARLOTTESVILLE, Va., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW...

Adial Pharmaceuticals Confirms Scheduling of Meetings with FDA and European Regulatory Agencies to Advance Clinical Development of AD04 for Alcohol Use Disorder

Type C meeting with FDA set for Second Quarter Plans in Place to Meet with Multiple Regulatory Agencies...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Adial Pharmaceuticals Inc (ADIL)

Outils de qualité professionnelle, pour des investisseurs individuels.

ADIL Actualités

Current Report Filing (8-k)

Adial Pharmaceuticals Provides Update on Regulatory Strategy for AD04 for Treatment of Alcohol Use Disorder

Adial Pharmaceuticals Schedules Business Update Conference Call

Current Report Filing (8-k)

Adial Pharmaceuticals Announces Closing of $0.75 Million At-The-Market Registered Direct Offering

Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)

Current Report Filing (8-k)

Adial Pharmaceuticals Announces Pricing of $0.75 Million At-The-Market Registered Direct Offering

Adial Pharmaceuticals Confirms Scheduling of Meetings with FDA and European Regulatory Agencies to Advance Clinical Development of AD04 for Alcohol Use Disorder

Adial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to Adenomed

Statement of Changes in Beneficial Ownership (4)

Current Report Filing (8-k)

Quarterly Report (10-q)

Adial Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Adial Pharmaceuticals Inc (ADIL) Actualités

Adial Pharmaceuticals Inc (ADIL)

Outils de qualité professionnelle, pour des investisseurs individuels.

ADIL Actualités

Current Report Filing (8-k)

Adial Pharmaceuticals Provides Update on Regulatory Strategy for AD04 for Treatment of Alcohol Use Disorder

Adial Pharmaceuticals Schedules Business Update Conference Call

Current Report Filing (8-k)

Adial Pharmaceuticals Announces Closing of $0.75 Million At-The-Market Registered Direct Offering

Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)

Current Report Filing (8-k)

Adial Pharmaceuticals Announces Pricing of $0.75 Million At-The-Market Registered Direct Offering

Adial Pharmaceuticals Confirms Scheduling of Meetings with FDA and European Regulatory Agencies to Advance Clinical Development of AD04 for Alcohol Use Disorder

Adial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to Adenomed

Statement of Changes in Beneficial Ownership (4)

Current Report Filing (8-k)

Quarterly Report (10-q)

Adial Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités